Llc ?sentiss Rus? Pharmaceutical Import Profile — Russia (DGFT 2022–2026)

Name: Llc ?sentiss Rus? Pharmaceutical Import Records from India — 6 Products, $12.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Llc ?sentiss Rus? — Pharmaceutical Importer Profile (2026) | 6 Products, $12.2M Trade | TransData Nexus

Llc ?sentiss Rus?

Pharmaceutical Importer · Russia · Antibiotics Focus · $12.2M Total Trade · DGFT Verified

Llc ?sentiss Rus? is a pharmaceutical importer based in Russia with a total trade value of $12.2M across 6 products in 4 therapeutic categories. Based on 254 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Llc ?sentiss Rus? sources from 1 verified Indian supplier, with Sentiss Pharma Private Limited accounting for 100.0% of imports.

Llc ?sentiss Rus? — Import Portfolio & Supplier Network

Llc ?sentiss Rus? import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Llc ?sentiss Rus??

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sentiss Pharma Private Limited	$39.4M	920	100.0%

Llc ?sentiss Rus? sources from 1 verified Indian supplier across 514 distinct formulations. The sourcing is highly concentrated — Sentiss Pharma Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Llc ?sentiss Rus? Import?

Formulation	Value	Ships
Kombinil eye and ear drops	$846.2K	18
Broxinac eye drops,0.09%(vial-dropper	$700.0K	14
Mydrimax eye drops(vial-dropper plastic)	$600.0K	12
Irifrin eye drops,2.5%(vial dropper plastic)5 ML no.1 bar#8901236010806 salt#phenylpherine b/n:n23388b md:12/23	$562.6K	12
Brinex m eye drops [brinzolamide]5ML 1%	$500.0K	10
Dancil eye and ear drops 0.3%(vial dropper plastic)5 ML no1 bar#8901236012305 salt#ofloxacin b/n:n23401md:12/23	$423.3K	12
Kombinil @ eye and ear drops	$400.0K	8
Diclo-f (diclofenac)eye drops 0.1%(vialdropper plastic)5 ML no.1 bar#8901236004607 salt#diclofenac	$358.1K	12
Irifrin bk eye drops 2.5%	$356.9K	8
Cipromed eye drops 0.3%(vial-dropper	$330.6K	8
Ophtolique eye drops(vial dropper	$328.2K	7
Inokain eye drops 0.4% solution plasticvials 5ML no. 1 bar#8901236003402 bulk drug#benoxinate	$322.7K	12
Inokain eye drops 0.4%solution plastic	$309.7K	8
Brinarga eye drops, 1%+0.5%(vial)5 mix	$300.0K	6
Santabrim eye drops 0.1% 5ML,bar:8901236020720,salt:brimonidine tartrate b/n:n23314,n23317 md:10/23	$300.0K	6

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ciprofloxacin	Antibiotics	$3.2M	64	1.1%	8
2	Ofloxacin	Advanced Antibiotics	$3.1M	62	1.0%	7
3	Levofloxacin	Antibiotics	$2.1M	43	1.9%	3
4	Tobramycin	Antibiotics	$2.1M	42	5.4%	3
5	Dexamethasone	Corticosteroids	$1.4M	27	0.7%	11
6	Vati	Ayurvedic & Herbal Products	$264.9K	16	1.0%	19

Llc ?sentiss Rus? imports 6 pharmaceutical products across 4 categories into Russia totaling $12.2M.

Llc ?sentiss Rus? — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Llc "Sentiss Rus" is a pharmaceutical importer and buyer based in Moscow, Russia. It operates as a subsidiary of Sentiss Pharma Private Limited, an Indian pharmaceutical company established in 1994. Sentiss Pharma specializes in manufacturing and distributing a range of pharmaceutical products, including ophthalmic, respiratory, otolaryngological, and wound care solutions.

As an importer, Llc "Sentiss Rus" plays a pivotal role in facilitating the distribution of Sentiss Pharma's finished pharmaceutical formulations within the Russian market. This includes a diverse portfolio of products such as tablets, capsules, syrups, and injections, catering to various therapeutic categories. The company's operations are integral to ensuring the availability of these products to meet the healthcare needs of the Russian population.

2Distribution Network

Llc "Sentiss Rus" maintains a strategic distribution network to effectively supply pharmaceutical products across Russia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are centralized in Moscow, facilitating efficient distribution throughout the country. The proximity to major transportation hubs in Moscow enables streamlined logistics, ensuring timely delivery of products to various regions within Russia.

The distribution network is designed to support the extensive range of products imported from India, ensuring that finished pharmaceutical formulations reach healthcare providers and consumers promptly. This infrastructure is crucial for maintaining the supply chain's integrity and meeting the demand for quality pharmaceutical products in the Russian market.

3Industry Role

Llc "Sentiss Rus" functions primarily as a pharmaceutical importer and distributor within Russia's healthcare sector. By sourcing finished pharmaceutical formulations from its parent company, Sentiss Pharma Private Limited, the subsidiary ensures the availability of a wide array of pharmaceutical products in the Russian market. This role is essential in bridging the gap between the manufacturing capabilities of Sentiss Pharma and the distribution requirements of the Russian healthcare system.

The company's position in the supply chain underscores its importance in maintaining the flow of pharmaceutical products from production to end-users. Through its import and distribution activities, Llc "Sentiss Rus" contributes significantly to the accessibility of quality healthcare solutions across Russia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Llc ?sentiss Rus?

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Llc "Sentiss Rus" exhibits a high degree of sourcing concentration, importing 97.8% of its products from a single supplier, Sentiss Pharma Private Limited. This exclusive sourcing strategy indicates a deep-rooted partnership and reliance on Sentiss Pharma for the supply of finished pharmaceutical formulations.

While such concentration can lead to favorable terms and streamlined operations, it also presents potential risks. Any disruptions in Sentiss Pharma's production or supply chain could directly impact Llc "Sentiss Rus"'s ability to meet market demand. However, the consistent volume of shipments and the long-standing relationship between the two entities suggest a stable and reliable supply chain.

The shipment data reveals a robust and dependable relationship, with 254 shipments over the period from 2022 to 2026. This consistency reflects effective coordination and mutual trust, mitigating potential risks associated with single-source dependency.

2Supply Chain Resilience

The resilience of Llc "Sentiss Rus"'s supply chain is closely tied to its exclusive sourcing from Sentiss Pharma Private Limited. This singular supplier relationship necessitates a high level of trust and reliability. While the lack of backup suppliers could pose challenges in the event of supply disruptions, the established partnership and consistent shipment history indicate a well-functioning and dependable supply chain.

Importing Pharmaceuticals into Russia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Russia

1Regulatory Authority & Framework

In Russia, the primary regulatory authority overseeing pharmaceutical imports is the Ministry of Health of the Russian Federation. This body is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Russian market.

Key legislation governing pharmaceutical imports includes the Federal Law on Circulation of Medicines, which outlines the requirements for the registration, importation, and distribution of medicinal products. Additionally, the Technical Regulations of the Customs Union (TR CU 021/2011) set forth safety requirements for medical devices and pharmaceutical products.

The marketing authorization pathway for Indian generics involves obtaining a Certificate of State Registration from the Ministry of Health. This process includes submitting comprehensive documentation, such as clinical trial data, manufacturing details, and quality control measures, to demonstrate compliance with Russian standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Russia mandate that all imported medicines be registered with the Ministry of Health. This registration process ensures that imported products meet the necessary safety and efficacy standards.

Good Manufacturing Practice (GMP) certification is a critical component of the import process. Russia recognizes GMP certificates from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the manufacturing facility's adherence to international quality standards.

Llc ?sentiss Rus? — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Llc "Sentiss Rus" focuses on importing a range of pharmaceutical products, with a significant emphasis on antibiotics, advanced antibiotics, and corticosteroids. This strategic focus aligns with the therapeutic needs prevalent in the Russian healthcare system, addressing common and critical health conditions.

The market demand for these therapeutic areas is driven by factors such as the prevalence of infectious diseases, respiratory conditions, and inflammatory disorders in Russia. By concentrating on these categories, Llc "Sentiss Rus" ensures that it meets the essential healthcare needs of the population, contributing to improved health outcomes.

2Sourcing Profile

Llc "Sentiss Rus" employs a sourcing strategy centered on generic drug formulations, primarily sourced from its parent company, Sentiss Pharma Private Limited. This approach allows the company to offer cost-effective pharmaceutical products without compromising on quality.

The preference for specific formulations, such as antibiotics and corticosteroids, reflects the company's commitment to addressing prevalent health issues in the Russian market. India's established reputation for producing high-quality generic pharmaceuticals positions it as a strategic partner in Llc "Sentiss Rus"'s procurement strategy.

3Market Positioning

Frequently Asked Questions — Llc ?sentiss Rus?

What products does Llc ?sentiss Rus? import from India?

Llc ?sentiss Rus? imports 6 pharmaceutical products across 4 categories. Top imports: Ciprofloxacin ($3.2M), Ofloxacin ($3.1M), Levofloxacin ($2.1M), Tobramycin ($2.1M), Dexamethasone ($1.4M).

Who supplies pharmaceuticals to Llc ?sentiss Rus? from India?

Llc ?sentiss Rus? sources from 1 verified Indian suppliers. The primary supplier is Sentiss Pharma Private Limited (100.0% of imports, $39.4M).

What is Llc ?sentiss Rus?'s total pharmaceutical import value?

Llc ?sentiss Rus?'s total pharmaceutical import value from India is $12.2M, based on 254 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Llc ?sentiss Rus? focus on?

Llc ?sentiss Rus? imports across 4 categories. The largest: Antibiotics (61.2%), Advanced Antibiotics (25.5%), Corticosteroids (11.1%).

Get Full Llc ?sentiss Rus? Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.